Kainos Group plc Admission of Shares to Trading (0968G)

TIDMKNOS

RNS Number : 0968G

Kainos Group plc

01 November 2018

1 November 2018

Kainos Group plc

("Kainos" or the "Company")

Admission of Shares to Trading

Kainos announces that an application has been made to the Financial Conduct Authority and the London Stock Exchange for the admission of 2,497,677 ordinary shares of 0.5 pence each (the "Shares") to the Official List.

The Shares were issued and allotted to satisfy employee share awards in relation to the Company's long term incentive plans, and SAYE plan, made to the Company's employees and, as issued, rank pari passu in all respects with the existing issued ordinary shares.

The Shares are expected to be admitted to the Official List and to trading on the London Stock Exchange on 6 November 2018.

For the purpose of the Disclosure Guidance and Transparency Rules, the Company's total issued ordinary share capital at 31 October 2018 is 120,453,209 ordinary shares. This figure may be used by shareholders in the Company as the denominator for calculations to determine if they have a notifiable interest in the Company under the Disclosure Guidance and Transparency Rules or if such interest has changed.

Kainos Group plc Legal Entity Identifier: 213800H2PQMIF3OVZY47

Ends

For further information, please contact:

Kainos via FTI Consulting LLP

Brendan Mooney, Chief Executive Officer

Richard McCann, Chief Financial Officer

Investec Bank plc +44 20 7597 5970

Patrick Robb / Sebastian Lawrence

Canaccord Genuity +44 20 7523 4606

Simon Bridges / Emma Gabriel

FTI Consulting LLP +44 20 3727 1000

Matt Dixon / Harry Staight

About Kainos

Kainos Group plc is a UK-based provider of Digital Services and Digital Platforms.

The Group's Digital Services include full lifecycle development and support of customised Digital Services for government and commercial customers. Kainos is also the leading European partner for Workday Inc. ('Workday') responsible for implementing Workday's innovative Software-as-a-Service (SaaS) platform for enterprise and, now, government customers.

The Group's Digital Platforms comprise specialised digital products in the mobile healthcare and automated testing arenas. Smart is an automated testing platform for Workday customers; Evolve Electronic Medical Records ('EMR') is the market leading product for the digitisation of patient notes in the Acute sector of the NHS; and Evolve Integrated Care ('IC') is a SaaS-based integrated care platform for the NHS and international healthcare providers.

Kainos has over 1,300 people across eleven offices in Europe and the USA, working interchangeably across its Services and Platforms divisions.

Kainos is listed on the London Stock Exchange (LSE: KNOS). For further information, please visit www.kainos.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCBUBDBDUGBGIB

(END) Dow Jones Newswires

November 01, 2018 11:57 ET (15:57 GMT)

Kainos (LSE:KNOS)
Historical Stock Chart
From Apr 2024 to May 2024